Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin (article published in 2015)

Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis

Q72198058

Evaluating the utility of circulating biomarkers of collagen synthesis in hypertrophic cardiomyopathy

Q87201746

N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin

Q24651908

Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study

Q33529398

Comparison the prognostic value of galectin-3 and serum markers of cardiac extracellular matrix turnover in patients with chronic systolic heart failure

Q34102031

Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans

Q34122713

Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis

Q34316944

Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction

Q34364121

Galectin-3: an open-ended story

Q34494555

Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study

Q34622450

The regulation of inflammation by galectin-3.

Q34991925

The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.

Q35002383

Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study

Q35680958

Systemic inflammation in heart failure--the whys and wherefores

Q36526913

New targets to treat the structural remodeling of the myocardium

Q37948286

Positioning of inflammatory biomarkers in the heart failure landscape

Q38105986

Galectin-3: a modifiable risk factor in heart failure

Q38208784

How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology

Q40224176

The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.

Q41744993

DIOL triterpenes block profibrotic effects of angiotensin II and protect from cardiac hypertrophy

Q41990989

The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells.

Q42003225

Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation

Q43411330

Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis

Q45020454

Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase

Q48430921

Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure

Q48482082

Aldosterone inhibits antifibrotic factors in mouse hypertensive heart

Q48538923

Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage.

Q50663556

Galectin-3 increase in endurance athletes.

Q50948642

ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary

Q58975486

Galectin-3 Mediates Aldosterone-Induced Vascular Fibrosis

Q61187743

P433

issue

P921

main subject

heart failure

Q181754

P304

page(s)

385-392

P577

publication date

2015-02-11

P1433

published in

European Journal of Heart Failure

Q5017954

P1476

title

Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin

P478

volume

Reverse relations

cites work (P2860)

Q87030568	April 2015 at a glance
Q86626402	Can circulating biomarkers identify heart failure patients at low risk?
Q64094041	Circulating Aminoterminal Propeptide of Type III Procollagen as a Biomarker of Cardiovascular Events in Patients Undergoing Hemodialysis
Q93261783	Echocardiographic diastolic function evolution in patients with an anterior Q-wave myocardial infarction: insights from the REVE-2 study
Q48157893	Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study
Q51008128	Firefighting in viral myocarditis - Extinguish galectin-3 to control the inflamed heart?
Q90073141	Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases
Q36297961	Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices
Q47644833	Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide vs. furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
Q50109537	Letter to the Editor regarding the article 'Left atrial volume index in patients with heart failure and severely impaired left ventricular systolic function: the role of established echocardiographic parameters, circulating cystatin C and galectin-3
Q55230733	Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure.
Q47843525	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis
Q99587532	Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Q30355765	The emerging role of Cardiovascular Magnetic Resonance in the evaluation of hypertensive heart disease.
Q38828267	The potential of targeting epigenetic regulators for the treatment of fibrotic cardiac diseases